| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005305973 |
| P356 | DOI | 10.1208/S12248-014-9687-3 |
| P932 | PMC publication ID | 4287298 |
| P698 | PubMed publication ID | 25366889 |
| P2093 | author name string | Li Di | |
| P2860 | cites work | Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum | Q72589601 |
| Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties | Q74663247 | ||
| Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability | Q75211567 | ||
| Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans | Q77781532 | ||
| Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue | Q79532645 | ||
| Intramolecular hydrogen bonding in medicinal chemistry | Q82995177 | ||
| A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life | Q87320077 | ||
| Albiglutide: first global approval | Q87953761 | ||
| Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix | Q24537504 | ||
| Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery | Q26863420 | ||
| Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance | Q27664086 | ||
| Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids | Q27685175 | ||
| The future of peptide-based drugs | Q28281702 | ||
| The druggable genome | Q29547361 | ||
| Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures | Q30670954 | ||
| No entry for TAT(44-57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides. | Q30763489 | ||
| Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins | Q31135530 | ||
| Phage display-derived peptides as therapeutic alternatives to antibodies | Q33203531 | ||
| Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells? | Q33257214 | ||
| Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity | Q33316512 | ||
| N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. | Q33329455 | ||
| Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides | Q33355086 | ||
| Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide | Q33723283 | ||
| Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices | Q33785066 | ||
| Intestinal permeation enhancers | Q33875824 | ||
| On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds | Q34030237 | ||
| Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic | Q34069846 | ||
| Clinical pharmacokinetics of depot leuprorelin | Q34135364 | ||
| Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. | Q34148307 | ||
| Cell-penetrating peptides: classes, origin, and current landscape | Q34215571 | ||
| Intestinal permeability of cyclic peptides: common key backbone motifs identified. | Q34318598 | ||
| Bicyclization and tethering to albumin yields long-acting peptide antagonists. | Q34454138 | ||
| Converting a peptide into a drug: strategies to improve stability and bioavailability | Q34609303 | ||
| Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action | Q35087618 | ||
| Challenges for the oral delivery of macromolecules | Q35096210 | ||
| Large-scale manufacture of peptide therapeutics by chemical synthesis | Q35158018 | ||
| Emerging Trends in Oral Delivery of Peptide and Protein Drugs | Q35570636 | ||
| Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice | Q35579541 | ||
| Interspecies scaling of protein drugs: prediction of clearance from animals to humans | Q35597373 | ||
| Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients | Q35826402 | ||
| Strategies to improve plasma half life time of peptide and protein drugs | Q36452632 | ||
| Therapeutic peptides: technological advances driving peptides into development | Q36627642 | ||
| Innovative approaches to anti-arrhythmic drug therapy. | Q36670460 | ||
| Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. | Q36740783 | ||
| Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. | Q37072064 | ||
| Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry | Q37243088 | ||
| Pharmacokinetics and dosage adjustment in patients with renal dysfunction. | Q37526589 | ||
| Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies | Q37585356 | ||
| Synthetic therapeutic peptides: science and market | Q37625355 | ||
| Protein and Peptide drug delivery: oral approaches | Q37666699 | ||
| Delivery of therapeutic proteins | Q37668486 | ||
| Vitamin B12 in drug delivery: breaking through the barriers to a B12 bioconjugate pharmaceutical | Q37815507 | ||
| Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs | Q37851140 | ||
| Peptides as therapeutics with enhanced bioactivity. | Q38029360 | ||
| Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. | Q38110433 | ||
| Future directions for peptide therapeutics development | Q38111100 | ||
| Multifaceted roles of disulfide bonds. Peptides as therapeutics. | Q38180456 | ||
| Predicting and improving the membrane permeability of peptidic small molecules. | Q39384465 | ||
| The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm. | Q39754683 | ||
| Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells | Q40135000 | ||
| A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists | Q40434802 | ||
| Enzymatic barriers for GI peptide and protein delivery | Q40438502 | ||
| Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects | Q40623355 | ||
| Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. | Q40716260 | ||
| Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. | Q40804196 | ||
| Ipamorelin, the first selective growth hormone secretagogue | Q40832148 | ||
| Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance(). | Q41515525 | ||
| Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity | Q41703787 | ||
| Dermorphin analogs: resistance to in vitro enzymatic degradation is not always increased by additional D-amino acid substitutions | Q42076102 | ||
| Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1. | Q42130360 | ||
| Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs | Q42199670 | ||
| Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage | Q42406502 | ||
| Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. | Q42478498 | ||
| Interspecies modeling and prediction of human exenatide pharmacokinetics | Q42680392 | ||
| Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate. | Q42716858 | ||
| Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase | Q42937196 | ||
| Hydrophobicity of peptides containing D-amino acids | Q43011461 | ||
| Recognition and oxidative metabolism of cyclodipeptides by hepatic cytochrome P450. | Q43581163 | ||
| Stapled peptide to enter human testing, but affinity questions remain | Q43869240 | ||
| In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes | Q44317184 | ||
| Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. | Q44587948 | ||
| Relationship between structure and permeability of dipeptide derivatives containing tryptophan and related compounds across human intestinal epithelial (Caco-2) cells | Q44707713 | ||
| Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide | Q45032005 | ||
| A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. | Q45267634 | ||
| The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide | Q45471927 | ||
| Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. | Q45913481 | ||
| Safe and effective permeation enhancers for oral drug delivery. | Q45988779 | ||
| Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. | Q46001611 | ||
| Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics | Q46055776 | ||
| Gastric retention and stability of lipidized Bowman-Birk protease inhibitor in mice | Q46129931 | ||
| Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides | Q46328799 | ||
| Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites | Q46375381 | ||
| Reversible lipidization for the oral delivery of salmon calcitonin | Q46445744 | ||
| Comparative genomic analysis of human and chimpanzee proteases | Q46702958 | ||
| An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis | Q46723219 | ||
| Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery | Q46851809 | ||
| Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs | Q46924880 | ||
| Whole body and brain distribution of [3H]cyclic [D-Pen2,D-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration | Q48399551 | ||
| Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. | Q51743679 | ||
| Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. | Q52306399 | ||
| Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers | Q56609520 | ||
| Peptide stability in drug development: a comparison of peptide reactivity in different biological media | Q67559229 | ||
| Pharmacokinetics of SMS 201-995 in healthy subjects | Q69888012 | ||
| Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P | Q71403164 | ||
| Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies | Q71955618 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 134-143 | |
| P577 | publication date | 2014-11-04 | |
| P1433 | published in | The AAPS Journal | Q10695361 |
| P1476 | title | Strategic approaches to optimizing peptide ADME properties | |
| P478 | volume | 17 |
| Q46220508 | 2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines 'Scientific'? (Part 1 - LCMS: small molecules, peptides and small molecule biomarkers). |
| Q64993130 | A Comprehensive Review on Current Advances in Peptide Drug Development and Design. |
| Q28390479 | A Mitochondrial-Targeted Nitroxide Is a Potent Inhibitor of Ferroptosis |
| Q38157419 | A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses |
| Q60959411 | Acute Toxicity of the Recombinant and Native Phα1β Toxin: New Analgesic from Spider Venom |
| Q92059928 | Advances in oral peptide therapeutics |
| Q96132105 | Advances in therapeutic peptides targeting G protein-coupled receptors |
| Q38990711 | An efficient liquid chromatography-high resolution mass spectrometry approach for the optimization of the metabolic stability of therapeutic peptides. |
| Q99547080 | Antimicrobial peptides - Advances in development of therapeutic applications |
| Q92126384 | Antiviral peptides as promising therapeutic drugs |
| Q89025809 | CPP-E1A fusion peptides inhibit CtBP-mediated transcriptional repression |
| Q26753265 | Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems |
| Q47773114 | Characterization and in vivo efficacy of a heptapeptide ODT formulation for the treatment of neurogenic bladder dysfunction |
| Q47579138 | Chemically Precise Glycoengineering Improves Human Insulin. |
| Q64068757 | Comparing sequence and structure of falcipains and human homologs at prodomain and catalytic active site for malarial peptide based inhibitor design |
| Q60949391 | Constrained α-Helical Peptides as Inhibitors of Protein-Protein and Protein-DNA Interactions |
| Q96954310 | Current status and future directions of high-throughput ADME screening in drug discovery |
| Q42656068 | Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease |
| Q44945151 | Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases |
| Q89386589 | Design and Development of a Cyclic Decapeptide Scaffold with Suitable Properties for Bioavailability and Oral Exposure |
| Q55316778 | Discovery of a novel potent peptide agonist to adiponectin receptor 1. |
| Q61796165 | Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug |
| Q48329419 | Enhancing the Antimicrobial Activity of Alamethicin F50/5 by Incorporating N-terminal Hydrophobic Triazole Substituents. |
| Q64099047 | Glycopeptides and -Mimetics to Detect, Monitor and Inhibit Bacterial and Viral Infections: Recent Advances and Perspectives |
| Q91752225 | Harnessing snake venom phospholipases A2 to novel approaches for overcoming antibiotic resistance |
| Q61815467 | Identification, Characterization, and Optimization of Integrin αβ₆-Targeting Peptides from a One-Bead One-Compound (OBOC) Library: Towards the Development of Positron Emission Tomography (PET) Imaging Agents |
| Q98906744 | Importance of structure-based studies for the design of a novel HIV-1 inhibitor peptide |
| Q52657761 | In Vitro ADME Properties of Two Novel Antimicrobial Peptoid-Based Compounds as Potential Agents against Canine Pyoderma. |
| Q41898671 | In vivo characterisation of a therapeutically relevant self-assembling 18 F-labelled β-sheet forming peptide and its hydrogel using positron emission tomography. |
| Q97531049 | Influence of Blood Collection Methods and Long-Term Plasma Storage on Quorum-Sensing Peptide Stability |
| Q39037677 | Lipopeptides as therapeutics: applications and in vivo quantitative analysis |
| Q57132668 | Lipophilicity prediction of peptides and peptide derivatives by consensus machine learning |
| Q92343691 | Marine Toxins and Nociception: Potential Therapeutic Use in the Treatment of Visceral Pain Associated with Gastrointestinal Disorders |
| Q47680427 | Molecular engineering solutions for therapeutic peptide delivery. |
| Q47797389 | N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors |
| Q92905229 | Nature-Derived Peptides: A Growing Niche for GPCR Ligand Discovery |
| Q64082816 | Novel Peptide Inhibitors for Lactate Dehydrogenase A (LDHA): A Survey to Inhibit LDHA Activity via Disruption of Protein-Protein Interaction |
| Q35824748 | Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors |
| Q58574209 | Nuclear factor-kappa B: Glucocorticoid-induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model |
| Q36221374 | Original insights on thrombospondin-1-related antireceptor strategies in cancer |
| Q92856776 | Pentapeptide Protects INS-1 Cells From hIAPP-Mediated Apoptosis by Enhancing Autophagy Through mTOR Pathway |
| Q47229048 | Peptibodies: An elegant solution for a long-standing problem. |
| Q42411952 | Peptide Developability at the Discovery-to-Development Interface--Current State and Future Opportunities |
| Q47590580 | Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics |
| Q42291656 | Peptide Macrocyclization Inspired by Non-Ribosomal Imine Natural Products |
| Q47933170 | Peptide Mediated Brain Delivery of Nano- and Submicroparticles: a Synergistic Approach. |
| Q60184483 | Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications |
| Q36033291 | Peptides and Peptide Analogs to Inhibit Protein-Protein Interactions |
| Q91836053 | Peptides as epigenetic modulators: therapeutic implications |
| Q89258058 | Pharmacokinetic Studies around the Mono- and Difunctionalization of a Bioavailable Cyclic Decapeptide Scaffold |
| Q47872785 | Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism. |
| Q93152946 | Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer's Disease |
| Q89478737 | Preclinical pharmacokinetic, biodistribution, radiation dosimetry, and toxicity studies of 99mTc-HYNIC-(Ser)3-LTVPWY: A novel HER2-targeted peptide radiotracer |
| Q47928226 | Progress in the formulation and delivery of somatostatin analogs for acromegaly |
| Q28817674 | Prospects of In vivo Incorporation of Non-canonical Amino Acids for the Chemical Diversification of Antimicrobial Peptides |
| Q52328552 | Scalable thioarylation of unprotected peptides and biomolecules under Ni/photoredox catalysis. |
| Q38767147 | Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment |
| Q43848407 | Software-aided approach to investigate peptide structure and metabolic susceptibility of amide bonds in peptide drugs based on high resolution mass spectrometry. |
| Q96954319 | Software-aided detection and structural characterization of cyclic peptide metabolites in biological matrix by high-resolution mass spectrometry |
| Q52679239 | Specific Amyloid Binding of Polybasic Peptides In Vivo Is Retained by β-Sheet Conformers but Lost in the Disrupted Coil and All D-Amino Acid Variants. |
| Q38640597 | Strategies of GnRH synthetic analogues determination in doping control: in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameters fluctuations as suitable biomarkers |
| Q47602413 | Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer |
| Q55365864 | Synthetic fermentation of β-peptide macrocycles by thiadiazole-forming ring-closing reactions. |
| Q36062167 | TANGO-Inspired Design of Anti-Amyloid Cyclic Peptides |
| Q38651596 | THPdb: Database of FDA-approved peptide and protein therapeutics |
| Q98192043 | The Critical Role of Passive Permeability in Designing Successful Drugs |
| Q38767234 | The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease |
| Q53699942 | The Potential for Connexin Hemichannels to Drive Breast Cancer Progression through Regulation of the Inflammatory Response. |
| Q64108951 | The Role of Toxins in the Pursuit for Novel Analgesics |
| Q64054927 | Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer |
| Q57706019 | Thermally Reduced Graphene Oxide Nanohybrids of Chiral Functional Naphthalenediimides for Prostate Cancer Cells Bioimaging |
| Q48105929 | Total Synthesis of Scytonemide A Employing Weinreb AM Solid-Phase Resin. |
| Q92123495 | Understanding interactions of Citropin 1.1 analogues with model membranes and their influence on biological activity |
| Q39044774 | Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines |
Search more.